Heller Samantha L, Plaunova Anastasia, Gao Yiming
NYU Grossman School of Medicine, Department of Radiology, New York, NY.
J Breast Imaging. 2021 Mar 20;3(2):135-143. doi: 10.1093/jbi/wbaa119.
Ductal carcinoma in situ (DCIS), breast cancer confined to the milk ducts, is a heterogeneous entity. The question of how and when a case of DCIS will extend beyond the ducts to become invasive breast cancer has implications for both patient prognosis and optimal treatment approaches. The natural history of DCIS has been explored through a variety of methods, from mouse models to biopsy specimen reviews to population-based screening data to modeling studies. This article will review the available evidence regarding progression pathways and will also summarize current trials designed to assess DCIS progression.
导管原位癌（DCIS），即局限于乳腺导管的乳腺癌，是一种异质性疾病。DCIS病例如何以及何时会突破导管发展为浸润性乳腺癌的问题，对患者的预后和最佳治疗方法都具有重要意义。人们通过多种方法探索了DCIS的自然病史，从小鼠模型到活检标本回顾，再到基于人群的筛查数据以及模型研究。本文将回顾有关进展途径的现有证据，并总结目前旨在评估DCIS进展的试验。
